DOCSLIB.ORG

CIRSE 2019 in the CIRSE Society App!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CIRSE 2019 in the CIRSE Society App! POCKET GUIDE ANNUAL MEETING AND POSTGRADUATE COURSE OF THE CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGICAL SOCIETY OF EUROPE featuring IDEAS Interdisciplinary Endovascular Aortic Symposium www.cirse.org Programme at a Glance – Saturday, September 7 08:00 09:00 10:00 11:00 12:00 13:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 FS 101 R117 HTS 201 A1 FS 301 R117 Technologies and Hot debates on Real world techniques: drug-eluting endovascular evolution and out- technologies management of standing questions claudication p47 p51 p55 CEC 104 A2 ERT 204 A2 FS 304 A1 Ilio-femoral Portal Superior vena venous stenting hypertension cava syndromes masterclass management p48 p53 p56 FS 102 R115 FC 202 R117 CEC 302 A2 Pancreatic cancer: Ablative Intrahepatic role of IR therapies: the cholangio- basics carcinoma p47 p52 p55 FC 103 R114 FS 203 R115 FS 303 R112 Mgmt. of benign Future trends in Lymphatic musculo-skeletal spine treatments interventions tumours p48 p52 p56 ERT 105 R112 VL 205 R116 CS 305 R116 Artificial Embolisation Fibroids and intelligence, adenomyosis machine learning p53 p57 and robotics in IR p49 IRT 206 R113 CM 306 R113 Future IR CIRSE meets SP 106 R116 technologies p54 APSCVIR p57 Introducing IR p50 CLP-HDT 1 R111 Central lines and ports p33 CD-HDT 1 R130 A closer look at closure devices p33 PMT-HDT 1 R132 Peripheral mechanical thrombectomy p35 SIM 1 Simulation Training – Prostatic artery embolisation: basics, current role and future perspectives (advanced) 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 08:00 09:00 10:00 11:00 12:00 13:00 ENDOVASCULAR PROGRAMME INTERVENTIONAL ONCOLOGY Session includes lectures that are recommended for EBIR preparation ARTERIAL INTERVENTION EMBOLISATION e-voting VENOUS INTERVENTION NEUROINTERVENTION AORTIC INTERVENTION IDEAS NON-VASCULAR INTERVENTION A: Auditorium NoS: News on IR MANAGEMENT R: Room Stage Area 13:00 14:00 15:00 16:00 17:00 18:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 15 30 WS 604 R133 FS 701 R117 Varicose veins Management of p63 real world CLI FP 601 R117 FIRST@CIRSE – p66 First data release on endovascular research p61 NoS 404 NoS OP 500 A1 ERT 602 A2 WS 702 R116 Peripheral Opening and Awards Colorectal liver Transcatheter interventions Ceremony metastases: arterial chemo- treatment with embolisation curative intent p59 p60 p62 p66 CBD 603 R115 WS 703 R133 Treatment Biopsies of abdominal fluid collections p62 p66 CEC 605 R112 Mgmt. of patients with benign prostate hyperplasia p63 FS 606 R116 Collecting and evaluating evidence in IR CLP-HDT 2 R111 p63 Central lines and ports p33 FP 607 R113 FP 704 R113 CD-HDT 2 R130 Spinal Biliary A closer look at interventions p64 interventions p67 closure devices p33 FP 608 R114 FP 705 R114 PMT-HDT 2 R132 Dialysis and Non-vascular Peripheral AV fistula interventions mechanical p65 p68 thrombectomy p35 FP 706 R134 Simulator Radiation safety Gallery issues p43 p69 Satellite Symposia Sat. p146-147 Symp. p148 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 15 30 13:00 14:00 15:00 16:00 17:00 18:00 CBD: Case-based Discussion FP: Free Paper Session IRT: IR Trainee Session CEC: Clinical Evaluation Course FS: Focus Session NoS: News on Stage CS: Controversy Session HDT: Hands-on Device Training SP: Student Programme ERT: Expert Round Table HL: Honorary Lecture VL: Video Learning Session FC: Fundamental Course HTS: Hot Topic Symposium WS: Workshop Programme at a Glance – Sunday, September 8 08:00 09:00 10:00 11:00 12:00 13:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 FS 901 A2 FS 1001 A2 The NICE Acute type B guidelines: nice or dissection not so nice? IDEAS p70 IDEAS p74 CEC 902 A1 FC 1002 R117 CS 1101 A1 Diabetic foot Update on Carotid artery drug-eluting disease p71 technologies p74 p77 ERT 903 R112 VL 1003 R116 Colorectal cancer Interventional lung metastasis oncology p71 p74 FC 904 R116 ERT 1004 A1 Pain management Vertebral augmentation: alive and kicking p72 p75 FS 905 R117 FS 1005 R112 Pre-operative Update on pelvic portal vein embolisation embolisation p72 p75 IRT 1006 R114 Building an IR career p76 EMT-HDT 1 R130 Embolisation: materials & tools – liquid agents p34 TA-HDT 1 R111 Tumour ablation – MWA p36 VV-HDT 1 R132 Varicose veins p38 SIM 2 Simulation Training – Basic principles of mechanical thrombectomy in ischaemic stroke (advanced) SED 1 R118 Safe sedation application during IR procedures p40-41 p149 Satellite Symposia p150-151 Sat. Symp. 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 08:00 09:00 10:00 11:00 12:00 13:00 ENDOVASCULAR PROGRAMME INTERVENTIONAL ONCOLOGY Session includes lectures that are recommended for EBIR preparation ARTERIAL INTERVENTION EMBOLISATION e-voting VENOUS INTERVENTION NEUROINTERVENTION AORTIC INTERVENTION IDEAS NON-VASCULAR INTERVENTION A: Auditorium NoS: News on IR MANAGEMENT R: Room Stage Area 13:00 14:00 15:00 16:00 17:00 18:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 15 30 WS 1303 A2 CBD 1401 A2 FS 1501 A2 Fundamentals My worst day Subacute and in EVAR in the chronic type B angiosuite 1 dissection IDEAS p80 IDEAS p81 IDEAS p86 ERT 1402 R112 WS 1502 R133 Aorto-iliac Radial access stenotic occlusive disease p81 p86 NoS 1204 NoS HL 1301 A1 WS 1403 R115 CBD 1503 R116 Embolisation Andreas Gruentzig Lecture Biliary IR salvage for p79 interventions abdominal HTS 1302 surgical disasters Does ATTRACT change our p82 p86 DVT management practice? CBD 1404 R116 p79-80 Arteriovenous malformations and lymphatics p82 AI 1405 A1 Amazing interventions p82 FP 1406 R113 FP 1504 R113 Ablation of liver Venous tumours interventions EMT-HDT 2 R130 p83 p87 Embolisation: materials & tools – FP 1407 R114 FP 1505 R134 liquid agents p34 Experimental Interventional studies in IR oncology beyond TA-HDT 2 R111 p84 liver p88 Tumour ablation – MWA p36 FP 1408 R133 FP 1506 R114 Aortic Peripheral VV-HDT 2 R132 interventions vascular disease Varicose veins p38 IDEAS p85 intervention 1 p89 Simulator Gallery p44 SED 2 R118 SED 3 R118 Safe sedation Safe sedation application application during IR during IR procedures procedures p40-41 p40-41 p158 Satellite Symposia Satellite Symposia Satellite Symposia p153-156 p156-157 p157-158 Sat. Symp. 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 15 30 13:00 14:00 15:00 16:00 17:00 18:00 CBD: Case-based Discussion FP: Free Paper Session IRT: IR Trainee Session CEC: Clinical Evaluation Course FS: Focus Session NoS: News on Stage CS: Controversy Session HDT: Hands-on Device Training SP: Student Programme ERT: Expert Round Table HL: Honorary Lecture VL: Video Learning Session FC: Fundamental Course HTS: Hot Topic Symposium WS: Workshop Programme at a Glance – Monday, September 9 08:00 09:00 10:00 11:00 12:00 13:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 ERT 1701 A2 FS 1801 A2 How I treat bad Endoleaks in EVAR necks in EVAR IDEAS p90 IDEAS p94 FS 1702 R112 FS 1802 R115 Endovascular Medical therapy masterclass: to improve intermittent outcomes of PAD claudication interventions p91 p94 FC 1704 R117 FS 1804 R116 Portomesenteric Dialysis vein thrombosis masterclass p92 p95 FS 1703 R116 ERT 1803 A1 ERT 1901 R112 Everything you Current mgmt. of Anaesthesia wanted to know metastatic lesions in IR activity about immuno- from breast cancer therapy in IR p91 p95 p97 CEC 1705 A1 FC 1805 R117 Trauma Peripheral arteriovenous p92 malformations p96 IRT 1806 R114 Clinical practice for trainees, residents and young IRs p96 EMT-HDT 3 R130 Embolisation: materials & tools – coils & plugs p34 TA-HDT 3 R111 Tumour ablation – RFA p37 ST-HDT 1 R132 Stroke thrombectomy p36 SIM 3 Simulation Training – Emergency embolisation in trauma: state-of-the-art (intermediate) SED 4 R118 Safe sedation application during IR procedures (advanced) p40-41 Sat. Symp. Satellite Symposia p159 p161-164 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 08:00 09:00 10:00 11:00 12:00 13:00 ENDOVASCULAR PROGRAMME INTERVENTIONAL ONCOLOGY Session includes lectures that are recommended for EBIR preparation ARTERIAL INTERVENTION EMBOLISATION e-voting VENOUS INTERVENTION NEUROINTERVENTION AORTIC INTERVENTION IDEAS NON-VASCULAR INTERVENTION A: Auditorium NoS: News on IR MANAGEMENT R: Room Stage Area 13:00 14:00 15:00 16:00 17:00 18:00 15 30 45 15 30 45 15 30 45 15 30 45 15 30 45 15 30 CBD 2103 A2 ERT 2201 A2 WS 2301 A2 My worst day in How to achieve Fundamentals the angiosuite 2 durability in in TEVAR F-/B-EVAR IDEAS p101 IDEAS p102 IDEAS p108 ERT 2205 R112 SFA: the unsolved question: angio- plasty vs. stent p104 NoS 2004 NoS FIQ 2101 A1 WS 2202 R133 WS 2302 R113 Interventional Film Interpretation Quiz Thermal Genitourinary oncology protection for IR interventions: ablative therapies basic and advanced p99 HTS 2102 p102 p108 Is renal tumour ablation ready for prime time? CBD 2203 R115 WS 2303 R114 p100 IR in Pulmonary and gynaecological bronchial artery emergencies embolisation p103 p108 FS 2204 R117 FP 2304 R115 New in endo- TIPS and portal EMT-HDT 4 R130 vascular throm- vein intervention Embolisation: bectomy p103 p109 materials & tools – FP 2206 R113 FP 2305 R133 coils & plugs p34 Prostate artery Musculoskeletal embolisation p105 interventions p110 TA-HDT 4 R111 Tumour ablation – FP 2207 R116 FP 2306 R134 RFA p37 Transarterial Embolotherapy ST-HDT 2 R132 approaches for Stroke throm- liver tumours p106 p111 bectomy p36 FP 2208 R114 GA 2308 R116 Peripheral vasc.
Load more

Recommended publications
  • RENAULT CLIO WILLIAMS Seite 15 RENAULT LAGUNA Seite 16 1998 ERÖFFNUNG DES TECHNOCENTRE Seite 17
    Renault MEILENSTEINE INHALT 120 JAHRE RENAULT – EIN BLICK ZURÜCK Vorwort Seite 3 1898 120 JAHRE RENAULT Seite 4 VOITURETTE Seite 5 1928 MONASIX Seite 6 1938 JUVAQUATRE Seite 7 1958 FLORIDE Seite 8 RENAULT DAUPHINE GORDINI Seite 9 1968 RENAULT 4 PLEIN AIR Seite 10 1973 ALPINE WIRD TEIL VON RENAULT Seite 11 1978 TRIUMPH IN LE MANS Seite 12 RENAULT 18 Seite 13 1988 RENAULT 19 Seite 14 1993 RENAULT CLIO WILLIAMS Seite 15 RENAULT LAGUNA Seite 16 1998 ERÖFFNUNG DES TECHNOCENTRE Seite 17 RENAULT MEILENSTEINE 2018 2 VORWORT 120 JAHRE RENAULT – EIN BLICK ZURÜCK Renault blickt 2018 nicht nur auf ein Rekordjahr mit dem fünften Verkaufszuwachs in Folge zurück, sondern auch auf 120 Jahre Unternehmensgeschichte. Im Dezember 1898 rollte mit der «Voiturette» das erste Fahrzeug der Marke auf die Strasse. Bereits der kleine Zweisitzer setzte mit seinem kettenlosen Direktantrieb einen neuen Standard im Automobilbau und lieferte damit die Blau- pause für die nächsten zwölf Jahrzehnte, in deren Verlauf Renault immer wieder mit Innovationen und neuen Fahrzeugkonzepten für Aufsehen sorgte. So ist 2018 auch das Jahr zahlreicher weiterer Jubiläen in der bewegten Renault Historie: Vor 80 Jahren kam der Juvaquatre auf den Markt, vor 60 Jahren debütierte die Floride, vor 40 Jahren triumphierte Renault in Le Mans, und vor 20 Jahren eröffnete das Unternehmen sein Technocentre, um nur ein paar davon zu nennen. Die vorliegende Übersicht beinhaltet die wichtigs- ten Renault Jubiläumstermine des Jahres. Viel Spass beim Blättern und Schmökern. Weitere Informationen und noch mehr Fotos finden Sie auf der Renault Pressewebsite www.media.renault.ch unter dem Menüpunkt «Groupe Renault», «Geschichte».
    [Show full text]
  • Argon Medical Devices Products Catalogue
    ARGON PRODUCTS CATALOGUE Argon Medical Devices Products Catalogue WWW.ARGONMEDICAL.EU.COM www.argonmedical.eu.com[ 1 ] ARGON PRODUCTS CATALOGUE WWW.ARGONMEDICAL.EU.COM [ 2 ] [ 3 ] ARGON PRODUCTS CATALOGUE Table of Contents Thrombus Management .....................................................5 Endomyocardial Biopsy ................................................... 63 • Option™ELITE Inferior Vena Cava Filter System ....................6 • Jawz™ Endomyocardial Biopsy (EMB) Forceps ................... 64 • Atrieve™ Vascular Snare Kit ����������������������������������������������������8 • Endomyocardial Biopsy Accessories ���������������������������������� 65 • V+Pad™ Hemostasis Pads ......................................................9 • CLEANERXT™ & CLEANER15™ Rotational Thrombectomy System ................................................................................. 10 Bone & Bone Marrow Biopsy .......................................... 67 • T-Lok™ Bone Marrow Biopsy Needles ................................. 68 • Bone Marrow Aspiration Needles....................................... 68 Drainage ............................................................................13 • Bone Marrow Harvest Needles .......................................... 69 • SKATER™ Single Step Drainage Catheters ......................... 15 • Pediatric Bone Marrow Access Needles ............................ 69 • SKATER™ Drainage Catheters ............................................. 16 • Osty-Core™ Bone Biopsy Needles ......................................
    [Show full text]
  • Contemporary Methods for the Treatment of Pulmonary Embolism — Is It Prime-Time for Percutaneous Interventions?
    Kardiologia Polska 2017; 75, 11: 1161–1170; DOI: 10.5603/KP.a2017.0125 ISSN 0022–9032 ARTYKUŁ SPECJALNY / STATE-OF-THE-ART REVIEW Contemporary methods for the treatment of pulmonary embolism — is it prime-time for percutaneous interventions? Marcin Kurzyna1, Arkadiusz Pietrasik2, Grzegorz Opolski2, Adam Torbicki1 1Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, European Health Centre Otwock, Centre of Postgraduate Medical Education, Otwock, Poland 2Department and Faculty of Cardiology, Medical University of Warsaw, Warsaw, Poland Marcin Kurzyna, MD, PhD. Since 1998 he has been a physician in the Intensive Care Unit, and since 2003 the Head of the Haemodynamic Lab in the National Institute for Lung Diseases. Cur- rently he is Deputy Head of the Department of Pulmonary Circulation, Thromboembolic Diseases, and Cardiology and an associate professor in the Centre of Postgraduate Medical Education in Warsaw. He was a Chairman of Working Group on Pulmonary Circulation of Polish Cardiac Society (2013–2015). He is a specialist in internal medicine and cardiology and has a PhD in respiratory medicine. His research interests are currently related to the role of invasive procedures in the diagnosis and treatment of pulmonary vascular diseases. Arkadiusz Pietrasik, MD, PhD is an assistant in the First Chair and Department of Cardiology, Medical University of Warsaw. He is an independent operator certified by the Association of Car- diovascular Interventions (AISN) of the Polish Cardiac Society. His research interests cover structural heart diseases, coronary artery diseases, intravascular visualisation techniques, and chronic throm- boembolic pulmonary hypertension. He is a coordinator of the Pulmonary Embolism Response Team (CELZAT) at the Central Clinical Hospital of the Medical University of Warsaw.
    [Show full text]
  • Stock Available with Stock Position
    scode generic measurement Formulation Stock Available [Customer Demand Annualy] Annual Consumption A003 ACETYLSALICYLIC ACID 300MG TABLET 3,170 12,240 4,177 A017 ANTACID CHEWABLE TABLETS TABLET CHEWABLE 221,950 646,560 386,286 A022 BACLOFEN 10MG TABLET 64,848 483,732 319,924 A038 CALCIUM LACTATE 300MG TABLET 266,000 1,797,612 1,172,351 A042 CARBIDOPA|LEVODOPA 10MG|100MG TABLET 145,200 1,661,940 1,560,315 A043 CARBIDOPA|LEVODOPA 25MG|250MG TABLET 2,850 A062 CLOMIPRAMINE HYDROCHLORIDE 25MG TABLET 320,000 1,731,612 976,556 A063 COLCHICINE 500µ TABLET 49,254 314,412 171,971 A073 DAPSONE 50MG TABLET 13,552 22,668 12,395 A077 DIGOXIN 0.0625MG TABLET 313,936 1,313,736 827,752 A089 DYDROGESTERONE 10MG TABLET 2,520 7,128 2,234 A094 ETHAMBUTOL HYDROCHLORIDE 400MG TABLET 3,864 15,012 9,882 A112 FRUSEMIDE 40MG TABLET 175,700 872,880 479,257 A113 FUSIDATE SODIUM 250MG TABLET 2,300 9,888 5,318 A115 GLYCERYL TRINITRATE 500µ TABLET 36,340 578,364 324,289 A119 HALOPERIDOL 0.5MG CAPSULE 49,448 363,552 429,849 A137 ISOSORBIDE DINITRATE 10MG TABLET 338,080 1,005,972 386,600 A149 LOPERAMIDE HYDROCHLORIDE 2MG CAPSULE 19,900 229,284 116,993 A154 MEDROXYPROGESTERONE ACETATE 5MG TABLET 1,000 5,592 3,626 A155 MEDROXYPROGESTERONE ACETATE 100MG TABLET 4,200 24,456 13,295 A172 MEXILETINE HCL 200MG CAPSULES 1,680 2,296 A176 METOCLOPRAMIDE 10MG TABLET 59,892 167,208 72,894 A179 NAPROXEN 250MG TABLET 56,636 158,316 26,261 A184 NITROFURANTOIN 50MG CAPSULE 11,220 77,112 37,419 A188 OESTROGENS CONJUGATED 0.625MG TABLET 1,764 9,696 7,716 A202 PHENOXYMETHYLPENICILLIN 250MG
    [Show full text]
  • Bodacc Bulletin Officiel Des Annonces Civiles Et
    o Quarante-quatrième année. – N 148 A ISSN 0298-296X Lundi 2 et mardi 3 août 2010 BODACCBULLETIN OFFICIEL DES ANNONCES CIVILES ET COMMERCIALES ANNEXÉ AU JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE DIRECTION DE L’INFORMATION Standard......................................... 01-40-58-75-00 LÉGALE ET ADMINISTRATIVE Annonces....................................... 01-40-58-77-56 Accueil commercial....................... 01-40-15-70-10 26, rue Desaix, 75727 PARIS CEDEX 15 Abonnements................................. 01-40-15-67-77 www.dila.premier-ministre.gouv.fr (8h30à 12h30) www.bodacc.fr Télécopie........................................ 01-40-15-72-75 BODACC “A” Ventes et cessions - Créations d’établissements Procédures collectives Procédures de rétablissement personnel Avis relatifs aux successions Avis aux lecteurs Les autres catégories d’insertions sont publiées dans deux autres éditions séparées selon la répartition suivante Modifications diverses..................................... $ BODACC “B” Radiations ......................................................... # Avis de dépôt des comptes des sociétés .... BODACC “C” Banque de données BODACC servie par les sociétés : Altares-D&B, EDD, Extelia, Questel, Tessi Informatique, Jurismedia, Pouey International, Scores et Décisions, Les Echos, Creditsafe, Coface services, Cartegie, La Base Marketing, Infolegale, France Telecom Orange, Telino et Maxisoft. Conformément à l’article 4 de l’arrêté du 17 mai 1984 relatif à la constitution et à la commercialisation d’une banque de données télématique des informations contenues dans le BODACC, le droit d’accès prévu par la loi no 78-17 du 6 janvier 1978 s’exerce auprès de la Direction de l’information légale et administrative. Le numéro : 2,80 € Abonnement. − Un an (arrêté du 19 novembre 2009 publié au Journal officiel du 21 novembre 2009) : France : 398,60 €. Pour l’expédition par voie aérienne (outre-mer) ou pour l’étranger : paiement d’un supplément modulé selon la zone de destination ; tarif sur demande Paiement à réception de facture.
    [Show full text]
  • Lab.RII Laboratoire De Recherche Sur L’Industrie Et L’Innovation
    UNIVERSITÉ DU LITTORAL CÔTE D’OPALE Lab.RII Laboratoire de Recherche sur l’Industrie et l’Innovation CAHIERS DU LAB.RII – DOCUMENTS DE TRAVAIL – N°289 Janvier 2015 LA CONTRIBUTION DU TECHNOCENTRE AU RENFORCEMENT DES CAPACITES D’INNOVATION DE RENAULT Ismail ELHSSANI 1 LA CONTRIBUTION DU TECHNOCENTRE AU RENFORCEMENT DES CAPACITES D’INNOVATION DE RENAULT GUYANCOURT TECHNOCENTRE’S CONTRIBUTION TO STRENGTHENING RENAULT'S INNOVATION CAPACITY Ismail ELHSSANI 1 Abstract: To be part of this industrial race, in order to made design, develop and manufacture, Renault is participating in this tough race by deploying quality means in research and development which enable it to penetrate the automotive market through its center of Guyancourt Technocentre in Paris, which represents a considerable asset in terms of innovation. © Laboratoire de Recherche sur l’Industrie et l’Innovation Université du Littoral Côte d’Opale, janvier 2015 1 MASTER 2 : Electronique et Instrumentation, ULCO 2 LA CONTRIBUTION DU TECHNOCENTRE AU RENFORCEMENT DES CAPACITES D’INNOVATION DE RENAULT GUYANCOURT TECHNOCENTRE’S CONTRIBUTION TO STRENGTHENING RENAULT'S INNOVATION CAPACITY Ismail ELHSSANI TABLE DES MATIERES INTRODUCTION 4 1. VERS DE LA CONSTITUTION DU TECHNOCENTRE 4 1.1. Le groupe Renault comme entreprise innovante 4 1.1.1. Origine du développement du groupe Renault 4 1.1.2. Les innovations notables de Renault 6 1.1.3. L’alliance Renault-Nissan 7 1.2. Technocentre Renault 7 1.2.1. La mise en place du technocentre 7 1.2.2. Domaines d’activités 8 2. CONTRIBUTION DU TECHNOCENTRE DANS L’INNOVATION 9 2.1. Les innovations réalisées par le technocentre 9 2.2.
    [Show full text]
  • Annual Meeting Delegate Handbook
    BSIR 2016 ANNUAL MEETING DELEGATE HANDBOOK 1 5TH-1 7TH NOVEMBER 2016 MANCHESTER CENTRAL MANCHESTER 1 MAJOR SPONSORS 2 CONTENTS PAGE CONTENTS 4 Welcome to BSIR 2016 5 Speaker Instructions 6-7 General Information & Social Events WEDNESDAY 4TH NOVEMBER 2015 9 Programme Day 1 10 Scientific Sessions 1 & 2 11 The Graham Plant Proessorship 2016 12 SIRNR Programme 13 Industry Showcases 14 Masterclasses & Workshops THURSDAY 5TH NOVEMBER 2015 15 Programme Day 2 16 Scientific Sessions 3 & 4 17 OOH Intervention Snapshot Survey 18 Masterclasses & Workshops 19 Industry Showcases FRIDAY 6TH NOVEMBER 2015 20 Programme Day 3 21 Scientific Sessions 5 & 6 22 BSIR/BSIRT Trainee Day Programme 24 BSIR Honorary Fellowships: Professor Mike Dake & Dr Giles Maskell 25 BSIR Gold Medal: Professor Anthony Watkinson 26 Wattie Fletcher Lecture: Dr Richard McWilliams 27 Graham Plant Lecturer 28-29 Faculty Biographies 30-31 Faculty Lists 32-33 Exhibition Plan 34 List of Exhibitors 36-46 Exhibitor Bios 48-49 SIRNR Section 50 BSIR AGM 53-61 BSIR Committee Reports 62 BSIR Membership Form 64-69 BSIR/BSIRT Trainee Day Essay Scholars 70-75 BSIR Abstract & Case Study Review 76 VASBI 2017 - Trainee Day Meeting Announcement 77-100 BSIR Abstracts - Scientific Sessions 1-6 101 VASBI 2017 - Meeting Announcement 102-107 BSIR Scientific & Educational Posters 108 The U Foundation 109 BSIR 2017 - Meeting Announcement 110 BSIR IOUK 2017 - Meeting Announcement 3 WELCOME TO BSIR 2016 Dear Colleagues, The theme of this year scientific program continues from the last year’s one which entails covering the widest possible aspects of interventional radiology within the limited conference time.
    [Show full text]
  • NUMC-CDM-Jan2019.Pdf
    Charge Code Charge Description Charge 0301001 D.R.Ceaserean Sect $11,302.20 0301002 D.R. D&C $2,692.50 0301003 D.R. Insert Lamnaria $873.81 0301004 D.R. Salting $1,626.87 0301005 D.R. Vag Delivery $8,073.00 0301009 D.R. Prep Room Visit $383.62 0301010 D.R.Pstprtm Tubal Lg $2,749.34 0301011 D.R.Shirodkar $3,892.36 0301012 D.R. H.I.P. Laser Tr $838.30 0301013 D.R. H.I.P. Cryothrp $838.30 0301014 D.R. Vbac $3,500.77 0301015 D.R. C/S After Attempt Vbac $3,648.06 0301016 D.R. Low Forceps Delivery $9,149.40 0301017 D.R. Vacuum Assisted Delivery $9,149.40 0301018 Dr Del. Other Ntrl/Artfcl Open $9,149.40 0302001 L.R. Nst/Oct Intl Te $547.02 0302002 L.R. Nst/Oct Sbsq Te $500.00 0302050 Antepartum Care 7> Visits Only $1,666.26 0401001 P-F Spromtry Vol Vnt $427.34 0401002 Spirometry Bef&Aft Bronchdilat $788.64 0401005 P-F Diffus(Sin.Brth) $438.03 0401006 P-F Flow Vol Loop $725.49 0401010 P-F Compliance Study $1,387.63 0401012 P-F Art Punc&Bld Col $315.70 0401013 P-F Intr Arterial Ca $320.77 0401016 P-F Laryn&Trachescpy $1,234.64 0401017 P-F Bronchoscopy $3,979.48 0401018 P-F Brnchscpy&Brshng $3,979.48 0401019 Bronchoscopy W/Biopsy(S) $3,979.48 0401020 P-F Brnc&Biop&Brshng $3,979.48 0401021 Bronchoscopy/Lung Bx Each $7,863.33 0401022 P-F Trnsthor Ne Biop $4,051.10 0401023 P-F Pleural Biopsy $4,051.10 0401034 P-F Bronc Provac Tst $725.49 0401035 ASPIRATE PLEURA W/O IMAGING $2,152.80 0401044 Bronchoscopy/Needle Bx Each $6,558.51 0401046 P-F Lungfunc Mbc/Mvv $300.32 0401048 P-F Airway Inhal Trt $491.92 0401051 P-F Pos Airway Press $491.92 0401054 P-F
    [Show full text]
  • IDEAS 2015 Pocket Guide General Information
    Interdisciplinary Endovascular Aortic Symposium IDEAS 2015 September 27-29 Lisbon/Portugal Interdisciplinary Endovascular Aortic Symopsium POCKET GUIDE POCKET GUIDE POCKET 2015 EAS INNOVATION | EDUCATION | INTERVENTION Cardiovascular and Interventional Radiological Society of Europe ID Scientific & Educational Programme * Corporate Activities 4 General Information from A to Z 10 Session Types Sunday - Scientific Programme 11 SUN Monday - Scientific Programme 14 MON Tuesday - Scientific Programme 17 TUE 19 Corporate Activities 22 Satellite Symposia 39 Learning Centres 48 Technical Exhibition 48 Alphabetical & Numerical List 54 Technical Exhibitors Guide 110 Radiation Protection Pavilion 124 Floor Plans * advertisement-free section in accordance with the document UEMS 2012/30 – the Accreditation of Live Educational Events of the EACCME® (article 33/34) Cardiovascular and Interventional Radiological Society of Europe Welcome Address Welcome to the inaugural IDEAS symposium! Keep an eye out for the Endovascular aortic therapies have long been of interest to in- CIRSE Society app update terventional radiologists, vascular surgeons and cardiologists alike – the option to treat the aorta in a minimally invasive New features and design in time for CIRSE 2015! way opens exciting therapeutic possibilities, but realising this dream has been anything but straightforward. Install the CIRSE 2015 event to ensure your access to the best toolkit for the Annual Meeting in Lisbon: Recent technological advances have brought with them fresh enthusiasm for minimally invasive repair of aortic aneurysms – a complex category of interventions that rely heavily on the skills of a well-trained multidisciplinary medical team. • New! paperless session evaluation The various professionals involved in this team all bring their • e-voting own essential skills to the table.
    [Show full text]
  • Percutaneous Transfemoral Repositioning of Malpositioned Central Venous Access Device: a Report of Two Cases
    Free full text available from Case Report www.cancerjournal.net Percutaneous transfemoral repositioning of malpositioned central venous access device: A report of two cases ABSTRACT Ashutosh Chauhan, 1 Placement of long term central venous access devices (CVAD) such as chemo ports and Hickman’s catheters are associated with a Kamal Pathak , Manomoy Ganguly definite risk of catheter tip malpositioning. As such, malpositioning runs a risk of venous thrombosis and related complications; it is imperative to reposition the catheter. Percutaneous transfemoral venous approach has been described as a minimally invasive and Departments of safe method for the repositioning. We present two cases in which the CVAD implanted in one subclavian vein got malpositioned in Surgical Oncology and 1Interventional Radiology, contra lateral subclavian vein. A percutaneous transfemoral venous approach utilizing 5 Fr angiographic catheter was successful in Army Hospital (R &R), repositioning of the catheters in both cases. Delhi, India For correspondence: Dr. Ashutosh Chauhan, KEY WORDS: Chemo port, Hickman’s catheter, malposition, repositioning Department of Surgical Oncology, Army Hospital (R &R), Delhi Cantt, Delhi-110 010, India. INTRODUCTION undergone modified radical mastectomy and was E-mail: bolubonkey@ referred to our Center for placement of chemo port rediffmail.com Long term Central Venous Access Devices (CVAD) to facilitate the planned adjuvant chemotherapy. A DOI: 10.4103/0973- are frequently utilized in oncological practice, chemo port was placed in the left subclavian vein 1482.63554 most commonly for chemotherapy and long term under general anesthesia using classical Seldinger PMID: ***** parenteral nutrition. CVAD insertion can be done technique. A check X-ray in the postoperative “blind” using the Seldinger technique or under period demonstrated that the catheter tip had radiological guidance, either by ultrasound or malpositioned into contra lateral subclavian fluoroscopy.[1] Malpositioning of the same is a vein [Figure 1a].
    [Show full text]
  • Perforation of the Great Vessels During Central Venous Line Placement
    Arch Intern Med. 1995 Jun 12;155(11):1225-8. Perforation of the great vessels during central venous line placement. Robinson JF1, Robinson WA, Cohn A, Garg K, Armstrong JD 2nd. Author information Abstract BACKGROUND: Placement of central venous lines for the administration of a variety of therapies has become common practice. The most severe complication of this procedure is perforation of a large vessel, with bleeding, infusion of fluids into an extravascular site, and death. It is not clear from currently available data how often this occurs, what risk factors are associated, and how this complication can be avoided. METHODS: We reviewed the records of all patients who were identified as having perforation of a major vessel during central venous line placement occurring between 1986 and 1993 at the University Hospital, the major teaching facility of the University of Colorado Health Sciences Center, Denver. Data collected included the age and sex of the patient, diagnosis, type of catheter and site of placement, operator means and time to the diagnosis of perforation, and outcome. RESULTS: Eleven such complications were identified and 10 of them are reviewed in detail. The overall incidence was less than 1%. Most complications occurred when the right subclavian vein approach was attempted, and they were thought to result from guidewire kinking during advancement of a vessel dilator. All medical specialties and levels of training were involved. Four of 10 patients died of immediate or subsequent complications of the perforation. CONCLUSIONS: Perforation of a great vessel is an uncommon, but often fatal, complication of central venous line placement.
    [Show full text]
  • La Fabuleuse Aventure Du S45. Ou 40 Ans D'histoire De Cars Renault
    Déjà parus dans la collection EDmONS CH. MASSIN 16-18, rue de l'Amiral Mouchez 75014 PARIS Nicolas Tellier LA ^*** W''!* ^ *"' ^ flS.iL - >.:J-J_a OU 40 ans d'histoire de cars Renault Du même auteur La Grande Aventure des Cars Chausson, Edijac 1988, 304 pages (épuisé) Conception graphique Patrick Legrand - Jean Lochu MAS SIN E. DIT E U R PREFACE L'année 1993 sera marquée par un événement qui ne saurait passer inaperçu de ceux qui s'intéressent de près ou de loin au transport de personnes: L'autocar Renault S45 ou S53 ou S105 ne sera plus fabriqué. Il aura tellement fait partie du paysage de nos campagnes et de nos villes que l'on s'étonne presque qu'il ne figure pas au livre des records, que ce soit en terme de longévité, de nombre d'autocars produits, de créneaux d'utilisation. Créé par les bureaux d'Etudes de la "Régie", l'autocar S45 était assemblé sur le site d'Annonay, contribuant fortement au développement de l'industrie locale dont il est devenu le principal fleuron. Outil de travail indispensable pour nos transporteurs professionnels, chacun d'eux en a la reconnaissance qu'il mérite et Renault VI. s'est appuyé sur cette préoccupation essentielle pour construire avec succès le Tracer qui le remplace, sans faire oublier son aîné. L'auteur du livre retrace la vie et l'œuvre de notre autocar; il l'a fait au terme de recherches longues et précises qui ont conduit au présent ouvrage auquel nous associons l'authenticité et la reconnaissance du constructeur.
    [Show full text]